Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | BRD4 | O60885 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15499089 | 0.83 | SLC7A11 (0.70) | KDM4EBRD4KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15499090 | 0.82 | ALDH1A1 (0.71) | KDM4EBRD4KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15499088 | 0.80 | BRD4 (0.71) | KDM4EBRD4KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15499071 | 0.76 | BRD4 (0.64) | KDM4EBRD4KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15986425 | 0.75 | KDM4E (0.70) | KDM4EKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22679256 | 0.74 | BRD4 (0.79) | BRD4KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL547543 | 0.73 | KDM4E (1.00) | KDM4EKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL15499066 | 0.72 | SLC7A11 (0.58) | KDM4EBRD4ALDH1A1POLBBRD3 | |
| SCHEMBL2243779 | 0.72 | KDM4E (0.60) | KDM4EKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL10834280 | 0.72 | BRD4 (0.74) | BRD4KMT2AALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066410-A1 | INHIBITORS OF BROMODOMAINS AS MODULATORS OF GENE EXPRESSION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066410-A1 | INHIBITORS OF BROMODOMAINS AS MODULATORS OF GENE EXPRESSION | NFKBIA, NFKB2, IKBKG | KDM4E 672/4885BRD4 23/4885KMT2A 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.